Alnylam to appeal claim construction ruling on two patents asserted against moderna

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced an update on its ongoing patent infringement litigation. on march 17, 2022, alnylam initiated litigation in the united states district court for the district of delaware against moderna for patent infringement. to date, in two separate actions against moderna, alnylam has sought to recover reasonable compensation for moderna's infringement of five alnylam paten.
ALNY Ratings Summary
ALNY Quant Ranking